Trials / Recruiting
RecruitingNCT06384378
Systemic and Central Inflammation in AD
Central and Peripheral Immune Cross-talk in Alzheimer's Disease and Their Modulation by a Novel Immunotherapy
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- The Methodist Hospital Research Institute · Academic / Other
- Sex
- All
- Age
- 50 Years – 86 Years
- Healthy volunteers
- Not accepted
Summary
Inflammation could provide a new focus for therapeutic intervention. In this study, we will measure blood and cerebrospinal fluid (CSF) inflammation biomarkers and compare them to measurements of brain glial activation obtained by positron emission tomography (PET). In addition, we will determine the effect of low-dose interleukin-2 (IL-2) immunotherapy, given over 22 weeks, on these inflammation biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 11C-ER176 | ER176 is a PET tracer that binds to the 18 kDa translocator protein (TSPO), which is expressed by activated microglia and astrocytes and is therefore an index of brain inflammation. |
Timeline
- Start date
- 2023-03-17
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
- First posted
- 2024-04-25
- Last updated
- 2024-04-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06384378. Inclusion in this directory is not an endorsement.